The global refractory gout market size is expected to reach USD 1,599.24 million by 2034, according to a new study by Polaris Market Research. The report "Refractory Gout Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Biological and Non-Biological Treatments), Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The refractory gout market is witnessing steady expansion, driven by the increasing prevalence of severe gout cases unresponsive to conventional therapies. Refractory gout, characterized by persistent symptoms despite standard treatment, requires advanced therapeutic approaches, which significantly contribute to market growth. The market is segmented into biological and non-biological treatments, with biological therapies gaining notable market share due to their targeted action and higher efficacy in managing complex cases. These treatments, which include monoclonal antibodies and enzyme inhibitors, are increasingly favored, boosting market demand and fostering market expansion.
The rising awareness among healthcare professionals and patients about the availability of innovative treatment options is another crucial factor driving market size. Hospitals and specialty clinics, as primary treatment providers for refractory gout, play a pivotal role in market growth by offering access to advanced therapies and expert care. This segment is expected to witness significant growth, supported by the increasing adoption of biologics and the availability of specialized facilities.
Technological advancements, ongoing research and development, and the approval of novel drugs are further enhancing the refractory gout market. Additionally, the growing geriatric population, which is more susceptible to severe gout, is contributing to the increasing market demand. Favorable government initiatives and healthcare policies aimed at improving access to advanced treatments also support market expansion.
Refractory Gout Market Report Highlights:
In terms of treatment type, the biological treatment segment holds the significant market share in the refractory gout market due to their broad application and efficacy in managing symptoms.
By distribution channel, the hospitals and specialty clinics segment is expected to witness significant growth over the forecast period, driven by their capacity to handle severe and complex cases.
North America holds the largest share of the refractory gout market, with its advanced healthcare infrastructure and high prevalence of gout.
Asia Pacific is expected to witness significant growth over the forecast period, owing to increasing healthcare investments and rising awareness of gout management in emerging economies.
Polaris Market Research has segmented the refractory gout market report on the basis of treatment type, distribution channel, and region:
By Treatment Type Outlook (Revenue USD Million, 2020-2034)
Biologics
Pegloticase (Krystexxa)
Canakinumab
Non-Biologics
NSAIDs
Corticosteroids
Colchicine
Uricosurics (e.g., probenecid)
By Distribution Channel Outlook (Revenue USD Million, 2020-2034)
Hospitals and Specialty Clinics
Retail Pharmacies
Online Pharmacies
By Regional Outlook (Revenue USD Million, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Refractory Gout Market Insights
4.1. Refractory Gout Market - Market Snapshot
4.2. Refractory Gout Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rising Demand for Biologics in Refractory Gout Treatment
4.2.1.2. Surging Focus on Personalized Medicine and Genetic Testing
4.2.2. Restraints and Challenges
4.2.2.1. High Treatment Costs
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Refractory Gout Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Refractory Gout Market, by Treatment Type
5.1. Key Findings
5.2. Introduction
5.2.1. Global Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
5.3. Biologics
5.3.1. Global Refractory Gout Market, by Biologics, by Region, 2020-2034 (USD Million)
5.3.2. Pegloticase (Krystexxa)
5.3.2.1. Global Refractory Gout Market, by Pegloticase (Krystexxa), by Region, 2020-2034 (USD Million)
5.3.3. Canakinumab
5.3.3.1. Global Refractory Gout Market, by Canakinumab, by Region, 2020-2034 (USD Million)
5.4. Non-Biologics
5.4.1. Global Refractory Gout Market, by Non-Biologics, by Region, 2020-2034 (USD Million)
5.4.2. NSAIDs
5.4.2.1. Global Refractory Gout Market, by NSAIDs, by Region, 2020-2034 (USD Million)
5.4.3. Corticosteroids
5.4.3.1. Global Refractory Gout Market, by Corticosteroids, by Region, 2020-2034 (USD Million)
5.4.4. Colchicine
5.4.4.1. Global Refractory Gout Market, by Colchicine, by Region, 2020-2034 (USD Million)
5.4.5. Uricosurics (e.g., probenecid)
5.4.5.1. Global Refractory Gout Market, by Uricosurics (e.g., probenecid), by Region, 2020-2034 (USD Million)
6. Global Refractory Gout Market, by Distribution Channel
6.1. Key Findings
6.2. Introduction
6.2.1. Global Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
6.3. Hospitals and Specialty Clinics
6.3.1. Global Refractory Gout Market, by Hospitals and Specialty Clinics, by Region, 2020-2034 (USD Million)
6.4. Retail Pharmacies
6.4.1. Global Refractory Gout Market, by Retail Pharmacies, by Region, 2020-2034 (USD Million)
6.5. Online Pharmacies
6.5.1. Global Refractory Gout Market, by Online Pharmacies, by Region, 2020-2034 (USD Million)
7. Global Refractory Gout Market, by Geography
7.1. Key Findings
7.2. Introduction
7.2.1. Refractory Gout Market Assessment, By Geography, 2020-2034 (USD Million)
7.3. Refractory Gout Market - North America
7.3.1. North America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
7.3.2. North America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)